{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:47:23Z","timestamp":1772203643961,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:00:00Z","timestamp":1584576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s11894-020-00759-1","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T10:02:48Z","timestamp":1584612168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Update on the Treatment of Behcet\u2019s Disease of the Small Bowel with Biologic Agents"],"prefix":"10.1007","volume":"22","author":[{"given":"Yehyun","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Hee","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,19]]},"reference":[{"issue":"1","key":"759_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/bor.0000000000000125","volume":"27","author":"JH Cheon","year":"2015","unstructured":"Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behcet\u2019s disease. Curr Opin Rheumatol. 2015;27(1):24\u201331. https:\/\/doi.org\/10.1097\/bor.0000000000000125.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"759_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5217\/ir.2017.15.3.311","volume":"15","author":"HJ Lee","year":"2017","unstructured":"Lee HJ, Cheon JH. Optimal diagnosis and disease activity monitoring of intestinal Behcet\u2019s disease. Intest Res. 2017;15(3):311\u20137. https:\/\/doi.org\/10.5217\/ir.2017.15.3.311.","journal-title":"Intest Res"},{"issue":"1","key":"759_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3349\/ymj.2016.57.1.22","volume":"57","author":"DH Kim","year":"2016","unstructured":"Kim DH, Cheon JH. Intestinal Behcet\u2019s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J. 2016;57(1):22\u201332. https:\/\/doi.org\/10.3349\/ymj.2016.57.1.22.","journal-title":"Yonsei Med J"},{"issue":"2","key":"759_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/den.12552","volume":"28","author":"J Arimoto","year":"2016","unstructured":"Arimoto J, Endo H, Kato T, Umezawa S, Fuyuki A, Uchiyama S, et al. Clinical value of capsule endoscopy for detecting small bowel lesions in patients with intestinal Behcet\u2019s disease. Dig Endosc. 2016;28(2):179\u201385. https:\/\/doi.org\/10.1111\/den.12552.","journal-title":"Dig Endosc"},{"issue":"2","key":"759_CR5","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s10620-012-2351-9","volume":"58","author":"YS Jung","year":"2013","unstructured":"Jung YS, Cheon JH, Park SJ, Hong SP, Kim TI, Kim WH. Clinical course of intestinal Behcet\u2019s disease during the first five years. Dig Dis Sci. 2013;58(2):496\u2013503. https:\/\/doi.org\/10.1007\/s10620-012-2351-9.","journal-title":"Dig Dis Sci"},{"issue":"5","key":"759_CR6","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3349\/ymj.2013.54.5.1084","volume":"54","author":"JJ Park","year":"2013","unstructured":"Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behcet\u2019s disease. Yonsei Med J. 2013;54(5):1084\u201390. https:\/\/doi.org\/10.3349\/ymj.2013.54.5.1084.","journal-title":"Yonsei Med J"},{"issue":"6","key":"759_CR7","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/ibd.21833","volume":"18","author":"YS Jung","year":"2012","unstructured":"Jung YS, Yoon JY, Hong SP, Kim TI, Kim WH, Cheon JH. Influence of age at diagnosis and sex on clinical course and long-term prognosis of intestinal Behce\u2019s disease. Inflamm Bowel Dis. 2012;18(6):1064\u201371. https:\/\/doi.org\/10.1002\/ibd.21833.","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"759_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4166\/kjg.2019.73.1.3","volume":"50","author":"CK Lee","year":"2007","unstructured":"Lee CK, Kim HJ. Pathogenesis and treatment of intestinal Behcet\u2019s disease. Korean J Gastroenterol. 2007;50(1):3\u20138.","journal-title":"Korean J Gastroenterol"},{"issue":"49","key":"759_CR9","doi-asserted-by":"publisher","first-page":"e5516","DOI":"10.1097\/md.0000000000005516","volume":"95","author":"G Emmi","year":"2016","unstructured":"Emmi G, Silvestri E, Bella CD, Grassi A, Benagiano M, Cianchi F, et al. Cytotoxic Th1 and Th17 cells infiltrate the intestinal mucosa of Behcet patients and exhibit high levels of TNF-alpha in early phases of the disease. Medicine. 2016;95(49):e5516. https:\/\/doi.org\/10.1097\/md.0000000000005516.","journal-title":"Medicine"},{"key":"759_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fimmu.2019.00665","volume":"10","author":"B Tong","year":"2019","unstructured":"Tong B, Liu X, Xiao J, Su G. Immunopathogenesis of Behcet\u2019s disease. Front Immunol. 2019;10:665. https:\/\/doi.org\/10.3389\/fimmu.2019.00665.","journal-title":"Front Immunol"},{"issue":"6","key":"759_CR11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00296-013-2838-5","volume":"34","author":"H Ideguchi","year":"2014","unstructured":"Ideguchi H, Suda A, Takeno M, Miyagi R, Ueda A, Ohno S, et al. Gastrointestinal manifestations of Behcet\u2019s disease in Japan: a study of 43 patients. Rheumatol Int. 2014;34(6):851\u20136. https:\/\/doi.org\/10.1007\/s00296-013-2838-5.","journal-title":"Rheumatol Int"},{"issue":"6","key":"759_CR12","first-page":"130","volume":"35 Suppl 108","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Fabiani C, Venerito V, Lapadula G, Iannone F, Cantarini L. Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behcet\u2019s disease. Clin Exp Rheumatol. 2017;35 Suppl 108(6):130\u20131.","journal-title":"Clin Exp Rheumatol"},{"issue":"24","key":"759_CR13","doi-asserted-by":"publisher","first-page":"e3863","DOI":"10.1097\/md.0000000000003863","volume":"95","author":"T Hibi","year":"2016","unstructured":"\u2022\u2022 Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine. 2016;95(24):e3863. https:\/\/doi.org\/10.1097\/md.0000000000003863. The first prospective open-label, single-arm, phase 3 multicenter study with infliximab in intestinal BD patients demonstrating efficacy of infliximab until week 46.","journal-title":"Medicine"},{"issue":"2","key":"759_CR14","first-page":"171","volume":"47","author":"J Zou","year":"2017","unstructured":"\u2022\u2022 Zou J, Ji DN, Shen Y, Guan JL, Zheng SB. Mucosal healing at 14 weeks predicts better outcome in low-dose infliximab treatment for Chinese patients with active intestinal Behcet\u2019s disease. Ann Clin Lab Sci. 2017;47(2):171\u20137. The latest prospective cohort study with infliximab in intestinal BD demonstrating that low dose (3.5\u00a0mg\/kg) of infliximab is also effective and mucosal healing at week 14 predicted clinical remission at week 30.","journal-title":"Ann Clin Lab Sci"},{"issue":"5","key":"759_CR15","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.cgh.2014.08.042","volume":"13","author":"S Tanida","year":"2015","unstructured":"Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet\u2019s disease. Clin Gastroenterol Hepatol. 2015;13(5):940\u20138.e3. https:\/\/doi.org\/10.1016\/j.cgh.2014.08.042.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"759_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5217\/ir.2017.15.3.395","volume":"15","author":"N Inoue","year":"2017","unstructured":"\u2022\u2022 Inoue N, Kobayashi K, Naganuma M, Hirai F, Ozawa M, Arikan D, et al. Long-term safety and efficacy of adalimumab for intestinal Behcet\u2019s disease in the open label study following a phase 3 clinical trial. Intest Res. 2017;15(3):395\u2013401. https:\/\/doi.org\/10.5217\/ir.2017.15.3.395. The prospective open-label, single-arm, phase 3 multicenter study with long-term (100\u00a0weeks) follow-up of intestinal BD patients treated with adalimumab.","journal-title":"Intest Res"},{"issue":"2","key":"759_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10067-016-3417-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G, Gentileschi S, Silvestri E, Fabiani C, et al. Adalimumab effectiveness in Behcet\u2019s disease: short and long-term data from a multicenter retrospective observational study. Clin Rheumatol. 2017;36(2):451\u20135. https:\/\/doi.org\/10.1007\/s10067-016-3417-4.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"759_CR18","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s12013-014-9860-4","volume":"69","author":"D Ma","year":"2014","unstructured":"Ma D, Zhang CJ, Wang RP, Wang L, Yang H. Etanercept in the treatment of intestinal Behcet\u2019s disease. Cell Biochem Biophys. 2014;69(3):735\u20139. https:\/\/doi.org\/10.1007\/s12013-014-9860-4.","journal-title":"Cell Biochem Biophys"},{"issue":"9","key":"759_CR19","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s10067-017-3627-4","volume":"36","author":"A Vitale","year":"2017","unstructured":"Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behcet\u2019s disease. Clin Rheumatol. 2017;36(9):2063\u20139. https:\/\/doi.org\/10.1007\/s10067-017-3627-4.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"759_CR20","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14397595.2017.1285857","volume":"27","author":"G Lopalco","year":"2017","unstructured":"Lopalco G, Emmi G, Gentileschi S, Guerriero S, Vitale A, Silvestri E, et al. Certolizumab pegol treatment in Behcet\u2019s disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol. 2017;27(6):1031\u20135. https:\/\/doi.org\/10.1080\/14397595.2017.1285857.","journal-title":"Mod Rheumatol"},{"issue":"7","key":"759_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R, et al. Anakinra treatment in drug-resistant Behcet\u2019s disease: a case series. Clin Rheumatol. 2015;34(7):1293\u2013301. https:\/\/doi.org\/10.1007\/s10067-013-2443-8.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"759_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000358125","volume":"228","author":"A Vitale","year":"2014","unstructured":"Vitale A, Rigante D, Caso F, Brizi MG, Galeazzi M, Costa L, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcet\u2019s disease: a case series. Dermatology. 2014;228(3):211\u20134. https:\/\/doi.org\/10.1159\/000358125.","journal-title":"Dermatology"},{"issue":"5","key":"759_CR23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s10067-015-3004-0","volume":"35","author":"G Emmi","year":"2016","unstructured":"Emmi G, Talarico R, Lopalco G, Cimaz R, Cantini F, Viapiana O, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet\u2019s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281\u20136. https:\/\/doi.org\/10.1007\/s10067-015-3004-0.","journal-title":"Clin Rheumatol"},{"issue":"6","key":"759_CR24","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.semarthrit.2015.11.012","volume":"45","author":"A Deroux","year":"2016","unstructured":"Deroux A, Chiquet C, Bouillet L. Tocilizumab in severe and refractory Behcet\u2019s disease: four cases and literature review. Semin Arthritis Rheum. 2016;45(6):733\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.11.012.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"759_CR25","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1053\/gast.2001.22556","volume":"120","author":"PV Hassard","year":"2001","unstructured":"Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet\u2019s disease: a case report. Gastroenterology. 2001;120(4):995\u20139. https:\/\/doi.org\/10.1053\/gast.2001.22556.","journal-title":"Gastroenterology"},{"issue":"5","key":"759_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gut.49.5.725","volume":"49","author":"SP Travis","year":"2001","unstructured":"Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL. Treatment of intestinal Behcet\u2019s syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001;49(5):725\u20138. https:\/\/doi.org\/10.1136\/gut.49.5.725.","journal-title":"Gut"},{"issue":"1","key":"759_CR27","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10350-004-6506-4","volume":"46","author":"MT Kram","year":"2003","unstructured":"Kram MT, May LD, Goodman S, Molinas S. Behcet\u2019s ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum. 2003;46(1):118\u201321. https:\/\/doi.org\/10.1007\/s10350-004-6506-4.","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"759_CR28","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3904\/kjim.2007.22.1.24","volume":"22","author":"JH Lee","year":"2007","unstructured":"Lee JH, Kim TN, Choi ST, Jang BI, Shin KC, Lee SB, et al. Remission of intestinal Behcet\u2019s disease treated with anti-tumor necrosis factor alpha monoclonal antibody (infliximab). Korean J Intern Med. 2007;22(1):24\u20137. https:\/\/doi.org\/10.3904\/kjim.2007.22.1.24.","journal-title":"Korean J Intern Med"},{"issue":"5","key":"759_CR29","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s10350-006-0813-x","volume":"50","author":"JS Byeon","year":"2007","unstructured":"Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behcet\u2019s disease: report of a case. Dis Colon Rectum. 2007;50(5):672\u20136. https:\/\/doi.org\/10.1007\/s10350-006-0813-x.","journal-title":"Dis Colon Rectum"},{"issue":"9","key":"759_CR30","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1002\/ibd.20457","volume":"14","author":"M Naganuma","year":"2008","unstructured":"Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behcet\u2019s disease. Inflamm Bowel Dis. 2008;14(9):1259\u201364. https:\/\/doi.org\/10.1002\/ibd.20457.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"759_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/MPG.0b013e3181346b60","volume":"46","author":"M Ugras","year":"2008","unstructured":"Ugras M, Ertem D, Celikel C, Pehlivanoglu E. Infliximab as an alternative treatment for Behcet disease when other therapies fail. J Pediatr Gastroenterol Nutr. 2008;46(2):212\u20135. https:\/\/doi.org\/10.1097\/MPG.0b013e3181346b60.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"16","key":"759_CR32","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.2169\/internalmedicine.51.8005","volume":"51","author":"Y Maruyama","year":"2012","unstructured":"Maruyama Y, Hisamatsu T, Matsuoka K, Naganuma M, Inoue N, Ogata H, et al. A case of intestinal Behcet\u2019s disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years. Intern Med. 2012;51(16):2125\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.51.8005.","journal-title":"Intern Med"},{"issue":"9","key":"759_CR33","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1097\/MIB.0b013e31828f19c9","volume":"19","author":"JH Lee","year":"2013","unstructured":"Lee JH, Cheon JH, Jeon SW, Ye BD, Yang SK, Kim YH, et al. Efficacy of infliximab in intestinal Behcet\u2019s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19(9):1833\u20138. https:\/\/doi.org\/10.1097\/MIB.0b013e31828f19c9.","journal-title":"Inflamm Bowel Dis"},{"issue":"17","key":"759_CR34","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2169\/internalmedicine.52.0589","volume":"52","author":"H Kinoshita","year":"2013","unstructured":"Kinoshita H, Kunisaki R, Yamamoto H, Matsuda R, Sasaki T, Kimura H, et al. Efficacy of infliximab in patients with intestinal Behcet\u2019s disease refractory to conventional medication. Intern Med. 2013;52(17):1855\u201362. https:\/\/doi.org\/10.2169\/internalmedicine.52.0589.","journal-title":"Intern Med"},{"issue":"2","key":"759_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10165-010-0370-y","volume":"21","author":"S Iwata","year":"2011","unstructured":"Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Hanami K, et al. Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behcet\u2019s disease. Mod Rheumatol. 2011;21(2):184\u201391. https:\/\/doi.org\/10.1007\/s10165-010-0370-y.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"759_CR36","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00535-013-0872-4","volume":"49","author":"T Hisamatsu","year":"2014","unstructured":"Hisamatsu T, Ueno F, Matsumoto T, Kobayashi K, Koganei K, Kunisaki R, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behcet\u2019s disease: indication of anti-TNFalpha monoclonal antibodies. J Gastroenterol. 2014;49(1):156\u201362. https:\/\/doi.org\/10.1007\/s00535-013-0872-4.","journal-title":"J Gastroenterol"},{"issue":"4","key":"759_CR37","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jgh.13612","volume":"32","author":"JH Cheon","year":"2017","unstructured":"Cheon JH. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2017;32(4):769\u201377. https:\/\/doi.org\/10.1111\/jgh.13612.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"759_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1136\/ard.2006.064279","volume":"66","author":"JA van Laar","year":"2007","unstructured":"van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behcet\u2019s disease? Ann Rheum Dis. 2007;66(4):565\u20136. https:\/\/doi.org\/10.1136\/ard.2006.064279.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"759_CR39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.crohns.2011.03.006","volume":"5","author":"C De Cassan","year":"2011","unstructured":"De Cassan C, De Vroey B, Dussault C, Hachulla E, Buche S, Colombel JF. Successful treatment with adalimumab in a familial case of gastrointestinal Behcet\u2019s disease. J Crohns Colitis. 2011;5(4):364\u20138. https:\/\/doi.org\/10.1016\/j.crohns.2011.03.006.","journal-title":"J Crohns Colitis"},{"issue":"2","key":"759_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5217\/ir.2015.13.2.166","volume":"13","author":"M Kimura","year":"2015","unstructured":"Kimura M, Tsuji Y, Iwai M, Inagaki M, Madian A, Yoshino T, et al. Usefulness of adalimumab for treating a case of intestinal Behcet\u2019s disease with trisomy 8 myelodysplastic syndrome. Intest Res. 2015;13(2):166\u20139. https:\/\/doi.org\/10.5217\/ir.2015.13.2.166.","journal-title":"Intest Res"},{"issue":"12","key":"759_CR41","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1002\/ibd.20869","volume":"15","author":"A Ariyachaipanich","year":"2009","unstructured":"Ariyachaipanich A, Berkelhammer C, Nicola H. Intestinal Behcet\u2019s disease: maintenance of remission with adalimumab monotherapy. Inflamm Bowel Dis. 2009;15(12):1769\u201371. https:\/\/doi.org\/10.1002\/ibd.20869.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"759_CR42","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000355341","volume":"88","author":"T Toyonaga","year":"2013","unstructured":"Toyonaga T, Nakase H, Matsuura M, Minami N, Yamada S, Honzawa Y, et al. Refractoriness of intestinal Behcet\u2019s disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature. Digestion. 2013;88(4):217\u201321. https:\/\/doi.org\/10.1159\/000355341.","journal-title":"Digestion"},{"issue":"5","key":"759_CR43","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1053\/gast.2001.28674","volume":"121","author":"WJ Sandborn","year":"2001","unstructured":"Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, et al. Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121(5):1088\u201394. https:\/\/doi.org\/10.1053\/gast.2001.28674.","journal-title":"Gastroenterology"},{"issue":"7","key":"759_CR44","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/s0016-5085(03)00382-2","volume":"124","author":"JM Van den Brande","year":"2003","unstructured":"Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology. 2003;124(7):1774\u201385. https:\/\/doi.org\/10.1016\/s0016-5085(03)00382-2.","journal-title":"Gastroenterology"},{"issue":"4","key":"759_CR45","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/art.22669","volume":"57","author":"J Braun","year":"2007","unstructured":"Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007;57(4):639\u201347. https:\/\/doi.org\/10.1002\/art.22669.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"759_CR46","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/rheumatology\/keq136","volume":"49","author":"A Dallocchio","year":"2010","unstructured":"Dallocchio A, Canioni D, Ruemmele F, Duquesne A, Scoazec JY, Bouvier R, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology. 2010;49(9):1694\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keq136.","journal-title":"Rheumatology"},{"issue":"6","key":"759_CR47","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1007\/s10620-015-4007-z","volume":"61","author":"A O\u2019Toole","year":"2016","unstructured":"O\u2019Toole A, Lucci M, Korzenik J. Inflammatory bowel disease provoked by etanercept: report of 443 possible cases combined from an IBD referral center and the FDA. Dig Dis Sci. 2016;61(6):1772\u20134. https:\/\/doi.org\/10.1007\/s10620-015-4007-z.","journal-title":"Dig Dis Sci"},{"issue":"2","key":"759_CR48","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.gastrohep.2016.01.011","volume":"40","author":"A Iriarte","year":"2017","unstructured":"Iriarte A, Zaera C, Bachiller-Corral J, Lopez-Sanroman A. Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy. Gastroenterol Hepatol. 2017;40(2):117\u201321. https:\/\/doi.org\/10.1016\/j.gastrohep.2016.01.011.","journal-title":"Gastroenterol Hepatol"},{"issue":"1","key":"759_CR49","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, et al. Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study. J Rheumatol. 2005;32(1):98\u2013105.","journal-title":"J Rheumatol"},{"issue":"7","key":"759_CR50","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s10067-008-0857-5","volume":"27","author":"V Curigliano","year":"2008","unstructured":"Curigliano V, Giovinale M, Fonnesu C, Cerquaglia C, Verrecchia E, Turco S, et al. Efficacy of etanercept in the treatment of a patient with Behcet\u2019s disease. Clin Rheumatol. 2008;27(7):933\u20136. https:\/\/doi.org\/10.1007\/s10067-008-0857-5.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"759_CR51","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s00393-013-1307-6","volume":"73","author":"RH Mohammed","year":"2014","unstructured":"Mohammed RH. Etanercept therapy in Behcet\u2019s disease. The tight control strategy in refractory disease. Z Rheumatol. 2014;73(7):650\u20136. https:\/\/doi.org\/10.1007\/s00393-013-1307-6.","journal-title":"Z Rheumatol"},{"issue":"12","key":"759_CR52","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1007\/s00296-012-2628-5","volume":"33","author":"S Watanabe","year":"2013","unstructured":"Watanabe S, Aizawa-Yashiro T, Tsuruga K, Kinjo M, Ito E, Tanaka H. A young girl with refractory intestinal Behcet\u2019s disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent. Rheumatol Int. 2013;33(12):3105\u20138. https:\/\/doi.org\/10.1007\/s00296-012-2628-5.","journal-title":"Rheumatol Int"},{"issue":"6","key":"759_CR53","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","volume":"34","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Lopalco G, Vitale A, Coladonato L, Rigante D, Lucherini OM, et al. Paradoxical mucocutaneous flare in a case of Behcet\u2019s disease treated with tocilizumab. Clin Rheumatol. 2015;34(6):1141\u20133. https:\/\/doi.org\/10.1007\/s10067-014-2589-z.","journal-title":"Clin Rheumatol"},{"issue":"6 Suppl 102","key":"759_CR54","first-page":"S34","volume":"34","author":"M Santos-Gomez","year":"2016","unstructured":"Santos-Gomez M, Calvo-Rio V, Blanco R, Beltran E, Mesquida M, Adan A, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behcet\u2019s disease: results of a multicentre open-label study. Clin Exp Rheumatol. 2016;34(6 Suppl 102):S34\u2013s40.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"759_CR55","first-page":"116","volume":"35 Suppl 108","author":"J Chen","year":"2017","unstructured":"Chen J, Chen S, He J. A case of refractory intestinal Behcet\u2019s disease treated with tocilizumab, a humanised anti-interleukin-6 receptor antibody. Clin Exp Rheumatol. 2017;35 Suppl 108(6):116\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"759_CR56","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jaut.2018.09.002","volume":"97","author":"G Di Scala","year":"2019","unstructured":"Di Scala G, Bettiol A, Cojan RD, Finocchi M, Silvestri E, Emmi G. Efficacy of the anti-IL 17 secukinumab in refractory Behcet\u2019s syndrome: a preliminary study. J Autoimmun. 2019;97:108\u201313. https:\/\/doi.org\/10.1016\/j.jaut.2018.09.002.","journal-title":"J Autoimmun"},{"key":"759_CR57","doi-asserted-by":"publisher","first-page":"2975631","DOI":"10.1155\/2019\/2975631","volume":"2019","author":"TG Achufusi","year":"2019","unstructured":"Achufusi TG, Harnee PS, Rawlins S. A rare case of new-onset ulcerative colitis following initiation of secukinumab. Case Rep Med. 2019;2019:2975631. https:\/\/doi.org\/10.1155\/2019\/2975631.","journal-title":"Case Rep Med"},{"key":"759_CR58","doi-asserted-by":"publisher","unstructured":"Fobelo Lozano MJ, Serrano Gimenez R, Castro FM. Emergence of inflammatory bowel disease during treatment with secukinumab. J Crohn\u2019s Colitis. 2018. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy063.","DOI":"10.1093\/ecco-jcc\/jjy063"},{"issue":"1","key":"759_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12969-017-0162-4","volume":"15","author":"S Valenti","year":"2017","unstructured":"Valenti S, Gallizzi R, De Vivo D, Romano C. Intestinal Behcet and Crohn\u2019s disease: two sides of the same coin. Pediatr Rheumatol Online J. 2017;15(1):33. https:\/\/doi.org\/10.1186\/s12969-017-0162-4.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"3","key":"759_CR60","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4291\/wjgp.v5.i3.228","volume":"5","author":"V Yazisiz","year":"2014","unstructured":"Yazisiz V. Similarities and differences between Behcet\u2019s disease and Crohn\u2019s disease. World J Gastrointest Pathophysiol. 2014;5(3):228\u201338. https:\/\/doi.org\/10.4291\/wjgp.v5.i3.228.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"4","key":"759_CR61","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","volume":"72","author":"EM Baerveldt","year":"2013","unstructured":"Baerveldt EM, Kappen JH, Thio HB, van Laar JA, van Hagen PM, Prens EP. Successful long-term triple disease control by ustekinumab in a patient with Behcet\u2019s disease, psoriasis and hidradenitis suppurativa. Ann Rheum Dis. 2013;72(4):626\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202392.","journal-title":"Ann Rheum Dis"},{"key":"759_CR62","doi-asserted-by":"publisher","unstructured":"Mirouse A, Barete S, Desbois AC, Comarmond C, Sene D, Domont F, et al. Long-term outcome of ustekinumab therapy for Behcet\u2019s disease. Arthritis Rheumatol. 2019. https:\/\/doi.org\/10.1002\/art.40912.","DOI":"10.1002\/art.40912"},{"issue":"6","key":"759_CR63","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","volume":"77","author":"G Hatemi","year":"2018","unstructured":"\u2022\u2022 Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et al. 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213225. The most recently updated recommendations for BD management.","journal-title":"Ann Rheum Dis"},{"key":"759_CR64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and\/or refractory Behcet\u2019s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67\u201374. https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005.","journal-title":"J Autoimmun"},{"issue":"1","key":"759_CR65","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/1756-185x.12732","volume":"20","author":"L Cantarini","year":"2017","unstructured":"\u2022\u2022 Cantarini L, Talarico R, Generali E, Emmi G, Lopalco G, Costa L, et al. Safety profile of biologic agents for Behcet\u2019s disease in a multicenter observational cohort study. Int J Rheum Dis. 2017;20(1):103\u20138. https:\/\/doi.org\/10.1111\/1756-185x.12732. A large multicenter observational cohort study highlighting the excellent long-term safety profile of anti-TNF-\u03b1 drugs in BD.","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"759_CR66","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.dld.2018.10.024","volume":"51","author":"N Sugimura","year":"2019","unstructured":"\u2022\u2022 Sugimura N, Mizoshita T, Sugiyama T, Togawa S, Miyaki T, Suzuki T, et al. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behcet\u2019s disease. Dig Liver Dis. 2019;51(7):967\u201371. https:\/\/doi.org\/10.1016\/j.dld.2018.10.024. A latest retrospective study confirming the efficacy of anti-TNF-\u03b1 mAbs in real-world situations.","journal-title":"Dig Liver Dis"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-020-00759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11894-020-00759-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-020-00759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T01:19:30Z","timestamp":1616116770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11894-020-00759-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,19]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1007\/s11894-020-00759-1","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,19]]},"assertion":[{"value":"19 March 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"24"}}